Select Page

KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019
602546.jpg

KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. 

DALLAS, March 20, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates.

The research paper comes from Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and the principal of Biomedical Science Research Group (BSRG).  Professor Osbourn and KALY CEO Frederick Ferri met last week to coordinate a phase two study of the pilot treatment.

The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.  In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.

The company has made recent advances in partnership with Puration, Inc. (USOTC: PURA) (“PURA”) developing a CBD extract for infusion into a beverage at a 25 mg concentration. The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (OTCQB: GNBT).

Leave a Reply

avatar

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!